Evidence of oxidative stress in the neocortex in incidental Lewy body disease

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 9, 2005, Pages 816-830

  Dalfó, Esther ^a   Portero Otín, Manuel ^c   Ayala, Victoria ^c   Martínez, Anna ^a   Pamplona, Reinald ^c   Ferrer, Isidre ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Universitat de Lleida Facultat de Medicina Sabadell   (Spain)

Author keywords

Cerebral cortex; Dementia with Lewy bodies; Oxidative stress; Parkinson disease

Indexed keywords

4 HYDROXYNONENAL; 4 HYDROXYNONENAL LYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SYNUCLEIN; ANTIOXIDANT; DOCOSAHEXAENOIC ACID; FATTY ACID; LYSINE; MALONALDEHYDE; MALONALDEHYDE LYSINE; MANGANESE SUPEROXIDE DISMUTASE; MOLECULAR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AMYGDALOID NUCLEUS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DEMENTIA WITH LEWY BODY; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTAL CORTEX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INCIDENTAL LEWY BODY DISEASE; LIPID PEROXIDATION; MALE; NEOCORTEX; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SPECTROMETRY; SUBSTANTIA NIGRA;

EID: 24644514279     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000179050.54522.5a     Document Type: Article

References (58)

1. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72
2. Burke RE. Parkinson's disease. In: Koliatsos VE, Ratan RR, Choi D, eds. Cell Death and Diseases of the Nervous System. Totowa, NJ: Humana Press, 1999:459-76
3. Gai WP, Yuan HX, Li XQ, Power JTH, Blumbergs PC, Jensen PH. In situ and in vitro study of colocalization and segregation of α-synuclein, ubiquitin and lipids in Lewy bodies. Exp Neurol 2000;166:324-33
4. Jellinger K, Mizuno Y. Parkinson's disease. In: Dickson D, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press, 2003:159-87
5. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998;95:369-473
6. Baba M, Nakajo S, Tu PH, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-84
7. Iwatsubo T. Aggregation of α-synuclein in the pathogenesis of Parkinson's disease. J Neurol 2003;250(suppl 3):11-14
8. Hashimoto M, Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 1999;9:707-20
9. Narhi L, Wood SJ, Stevenson S, et al. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem 1999;274: 9843-46
10. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sundsmo M, Mashliah E. Oxidative stress induces amyloid-like aggregates formation of NACP/α-synuclein in vitro. Neuroreport 1999;10:717-21
11. Paik SR, Shin HJ, Lee JM. Metal-catalyzed oxidation of α-synuclern in the presence of Copper(II) and hydrogen peroxide. Arch Biochem Biophys 2000;378:269-77
12. Kosaka K, Iseki E. Diffuse Lewy body disease within the spectrum of Lewy body diseases. In: Perry RH, McKeith IG, Perry EK, eds. Dementia With Lewy Bodies. Cambridge: Cambridge University Press, 1996: 238-47
13. Ince PG, Perry EK, Morris CM. Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome. Brain Pathol 1998;8:299-324
14. Markesberry WR, Montine TJ, Lovell MA. Oxidative alterations in neurodegenerative diseases. In: Mattson MP, ed. Pathogenesis of Neurodegenerative Diseases. Totowa, NJ: Humana Press, 2001:21-51
15. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53 (suppl 3):S26-38
16. Hsu LJ, Sagara Y, Arroyo A, et al. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;17:401-10
17. Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004;304:448-52
18. Perry TL, Godin DV, Hansen S. Parkinson's disease: A disorder due to nigral glutathione deficiency. Neurosci Lett 1982;33:305-10
19. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease patients. Genomics 1994;17:171-84
20. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 1988;86:321-31
21. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in Parkinson's substantia nigra. J Neurochem 1989;53:692-97
22. Ceballos I, Lafon M, Javoy-Agid F, et al. Superoxide dismutase and Parkinson's disease. Lancet 1990;335:1035-36
23. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's disease but not in incidental Lewy body disease. J Neurochem 1997;69:1326-29
24. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998;70:268-75
25. Dexter DT, Carter C, Agid F. Lipid peroxidation as a cause of nigral death in Parkinson's disease. Lancet 1986;2:639-40
26. Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 1996;93:696-701
27. Shelley ML. 4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med 1998;25:169-74
28. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-9
29. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998;13:24-3
30. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson's disease and diffuse Lewy body disease. Brain Res 1996;737:195-200
31. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-203
32. Zhang J, Perry G, Smith MA, et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999;154:1423-29
33. Duda JE, Giasson BI, Mabon ME, Lee VMY, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body disease. Ann Neurol 2002;52:205-10
34. Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2-deoxyguanosine) is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204
35. ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-14
36. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000;1498:99-111
37. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
38. Braak H, Braak E. Temporal sequence of Alzheimer's disease-related pathology. In: Peters A, Morrison JH, eds. Cerebral Cortex, vol 14: Neurodegenerative and Related Changes in Structure and Function of Cerebral Cortex. New York: Kluwer Academic/Plenum Publishers, 1999:475-512
39. McKeith IG, Galasko D, Kosaka F, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-24
40. Pamplona R, Portero-Otin M, Requena J, Gredilla R, Barja G. Oxidative, glycoxidative and lipoxidative damage to rat heart mitochondrial proteins is lower after 4 months of caloric restriction than in age-matched controls. Mech Ageing Dev 2002;123:1437-46
41. Requena JR, Chao CC, Levine RL, Stadtman ER. Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. Proc Natl Acad Sci U S A 2001;98: 69-74
42. Pamplona RD, Dalfó E, Ayala Y et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer's disease and identification of lipoxidation targets. J Biol Chem 2005;280:21522-30
43. Cosgrove JP, Church DF, Pryor WA. The kinetics of the autoxidation of polyunsaturated fatty acids. Lipids 1987;22:299-304
44. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997;272:20313-16
45. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44
46. Castellani RJ, Perry G, Siedlak SL, et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 2002;319:25-28
47. Sharon R, Goldberg MS, Bar-Josef I, et al. α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A 2001;98:9110-15
48. Sharon R, Bar-Joseph I, Frosch MP, et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003;37:583-95
49. 2 with unsaturated fatty acids. J Biol Chem 1983;258:4759-61
50. Munch G, Luth HJ, Wong A, et al. Cross-linking of alpha-synuclein by advanced glycation end-products-an early pathophysiological step in Lewy body formation? J Chem Neuroanat 2000;20:253-57
51. Kamelija Z. 4-Hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 2003;24:293-303
52. Norris EH, Giasson BI. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. Antioxid Redox Signal 2005;7:672-84
53. Uversky VN, Li J, Souillac P, et al. Biophysical properties of the synucleins and their propensities to fibrillate: Inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 202;(277):11970-78
54. Hashimoto M, Bar-on P, Ho G, et al. β-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J Biol Chem 2004;279:23622-29
55. Williams MD, Van Remmen H, Conrad CC, et al. Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. J Biol Chem 1998;273: 28510-15
56. Melov S, Coskun P, Patel M, et al. Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc Natl Acad Sci U S A 1999;96:846-51
57. Hinerfeld D, Traini MD, Weinberger RP et al. Endogenous mitochondrial oxidative stress: Neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in Superoxide dismutase 2 null mice. J Neurochem 2004;88:657-67
58. Omar RA, Chyan YJ, Andorn AC, et al. Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease. J Alzheimers Dis 1999;1:139-45